RS Medical Corp.

Celebrating 100 years of caring for childrenMONTREAL, Oct. 04, 2024 (GLOBE NEWSWIRE) -- The 36th edition of the Canada Shrine Bowl will take place on Saturday, October 5 at 1 p.m. at Concordia Stadium, 7200 Sherbrooke Street West in Montreal. Each year, the game raises awareness about our patients and the pediatric specialty care thousands of them receive annually. Shriners Children’s Canada will be celebrating its 100th anniversary this year and has provided pediatric specialty care to thousands of patients over that time. This year’s game will also feature two patient ambassadors, Finley and Émerick, to proudly represent the hospital. This year's matchup is between the Concordia University Stingers against the Sherbrooke University Vert & Or. The public is invited to attend this annual event in support of Shriners Hospitals for Children Canada. Kevin Regimbald, head coach of the Vert & Or, and Brad Collinson, head coach of the Concordia Stingers, are all set for this superb sporting match between the two teams. This year, Montreal Alouettes player, Kristian Matte, will be the guest of honor. Accompanied by the Karnak Shriners, he will co-chair the opening and closing ceremonies of the game. Finley Finley was born with congenital scoliosis, missing and misshapen vertebrae, along with several rib anomalies. In addition to these spinal conditions, she faces spina bifida occulta, ketotic hypoglycemia, and severe asthma. Despite these challenges, Finley has never let her diagnoses define her. Since the age of 1, she has been traveling from Calgary to Montreal to see Dr. Ouellet at Shriners Hospitals for Children Canada. Thanks to the expert care she receives, Finley can enjoy her favorite activities—swimming, biking, gymnastics, and dancing. Her greatest joy comes from doing handstands and cartwheels, proving that nothing can hold her back! Émerick Émerick, 8 years old, was diagnosed with cerebral palsy, which made it hard for him to move. After a long, three-year wait for surgery at another hospital, his family found hope at Shriners Hospitals for Children Canada, known for its quick and excellent care. Within months, Émerick had a life-changing surgery called selective dorsal rhizotomy, which has helped him gain independence. Now, he can kick a soccer ball, walk with special aids, and stand longer without support. In just six months, Émerick has made incredible progress, showing his determination and the amazing support he has received. The public is welcome to attend the Shrine Bowl. The doors will open at 11:00 am on Saturday, October 5. To purchase tickets, go to Stingers.ca | Buy Tickets. If you cannot attend the game but still wish to donate for our patients, you can send an e-transfer to moncontribution@shrinenet.org (include your full name and address to receive a tax receipt). About Shriners Hospitals for Children Canada Established in Montreal in 1925, Shriners Hospital for Children ─ Canada is the only Canadian facility within the extensive Shriners Hospitals network. A bilingual hospital, it offers ultra-specialized acute orthopedic care to children from Canada, the United States and around the world. The hospital's mission is to promote health and provide treatment and rehabilitation for infants, children and young adults with orthopedic and neuromuscular conditions such as scoliosis, osteogenesis imperfecta, clubfoot, hip dysplasia and cerebral palsy. The hospital is committed to excellence and innovation in clinical practice, research and education. Affiliated with McGill University, the hospital enables resident physicians and healthcare professionals to take advantage of its facilities on the Glen site to further their training and experience. In addition to offering a patient- and family-centered care environment, the hospital is present in communities across Canada through telemedicine, outreach clinics and satellite clinics. Laure Moureaux, Communications Advisor, Shriners Hospitals for Children Canada 514-282-7222 / Cell: 514-207-2267, lmoureaux@shrinenet.org Chloe Ricciardi, Public Relations, Concordia University 514-796-7969, chloe.ricciardi@concordia.ca

MONTREAL, Sept. 26, 2024 (GLOBE NEWSWIRE) -- From September 28 to October 1, the Shriners Hospitals for Children - Canada will host the 4th International Symposium on Arthrogryposis. Organized in collaboration with the other Montreal pediatric centers - CHU Sainte-Justine, Centre de réadaptation Marie Enfant and Montreal Children's Hospital - the symposium will take place at the Hôtel Omni Mont-Royal, 1050 Sherbrooke Street West. Pre-conference workshops will be held on Saturday, September 28 at the Shriners Hospitals for Children - Canada. Arthrogryposis is a group of rare diseases that occur in around 1 in 3,000 children. Arthrogryposis manifests itself as joint stiffness, present from birth and affecting all four limbs to varying degrees. It may be accompanied by other signs: skeletal, visceral or neurological. People with arthrogryposis live with a limited range of movement, often restricting their participation in daily activities. Arthrogryposis is one of a wide range of so-called fetal immobility syndromes, encompassing a multitude of neurological and muscular abnormalities whose inventory is not yet complete. Over the course of four days, experts from around the world will discuss ways of approaching and treating this pathology, as well as the latest research projects in progress. For Dr. Reggie Hamdy and Dr. Noémi Dahan-Oliel, co-chairs of the scientific and organizing committees, the need for this 4th international symposium is clear. Noémi Dahan-Oliel, clinical researcher and associate professor at McGill University, explains: “By promoting knowledge sharing and networking among an international community of experts and people living with this condition, we are on the lookout for scientific advances and discoveries that will enable optimal evidence-based care. One of our Quebec stars, Luca “Lazylegz” Patuelli, www.lucapatuelli.com, a member of the organizing committee for this 4th edition of the international symposium, will perform a dance show on Sunday, September 29 at the Omni Hotel's Salle Pierre de Coubertin during the cocktail reception at 5:45 pm. Luca embodies the “can-do attitude” of people living with a rare disease. He is proof that support for patients and families, as called for by Quebec's policy on rare diseases, is not only an inescapable necessity, but also a source of wealth.” “The Shriners Healthcare Network is at the forefront of clinical advancements, and its Genomics Institute seeks to better understand the genetic causes of rare diseases such as arthrogryposis. It's by working together with clinicians, researchers and people living with arthrogryposis that we can learn, innovate and move forward to meet the needs of this community,” says Reggie Hamdy, MD, MSc (Ortho) FRCSC, orthopaedic surgeon and director of the Arthrogryposis Clinic at the Shriners in Montréal. Several patients and families living with arthrogryposis will also be there speaking about the care they received and their life experiences. To view the symposium program and find out more about the guest speakers: https://event.fourwaves.com/fr/amcinternationalsymposium/pages The first international symposium on arthrogryposis was held in 2007 in Birmingham, UK, to discuss different aspects of care for people with arthrogryposis. These learnings set the tone for the second symposium, held in St Petersburg, Russia, in 2014. Clinical and research advances made in the field of arthrogryposis were shared at the 3rd symposium in Philadelphia, USA, in 2018. The hospital, in collaboration with other Montreal pediatric facilities, is proud to welcome the 4th International Arthrogryposis Symposium to Montreal! About Shriners Hospitals for Children – Canada Established in Montreal in 1925, Shriners Hospital for Children ─ Canada is the only Canadian facility within the extensive Shriners Hospitals network. A bilingual hospital, it offers ultra-specialized acute orthopedic care to children from Canada, the United States and around the world. The hospital's mission is to promote health and provide treatment and rehabilitation for infants, children and young adults with orthopedic and neuromuscular conditions such as scoliosis, osteogenesis imperfecta, clubfoot, hip dysplasia and cerebral palsy. The hospital is committed to excellence and innovation in clinical practice, research and education. Affiliated with McGill University, the hospital enables resident physicians and healthcare professionals to take advantage of its facilities on the Glen site to further their training and experience. In addition to offering a patient- and family-centered care environment, the hospital is present in communities across Canada through telemedicine, outreach clinics and satellite clinics. Information: Emmanuelle RondeauCommunicationsShriners Hospitals for Children – CanadaTel.: 514-282-6990; Cell.: 514-207-1057erondeau@shrinenet.org A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7dc067b6-e47b-49a5-99fd-8507debbcdf2

心力衰竭（HF）是心血管疾病终末阶段，患者数量超千万，《欧洲预防心脏病学》的一项研究显示，全球心力衰竭患者的数量从1990年的3350万增加到2017年的6430万，几乎翻了一番。心衰患者左心扩张导致二尖瓣前后叶闭合不全，引起血液通过二尖瓣反流或渗漏，这就是功能性/继发性二尖瓣反流（FMR/SMR），其实就类似于门的门框尺寸不对产生缝隙，导致冷空气从缝隙漏进来，而热空气会从房间里漏出来。这会进一步减少心脏输送到身体其他部位的含氧血液量，从而损害心脏功能，使心衰恶化。据统计，高达74%的心衰患者都患有FMR。随着2013年和2019年经导管二尖瓣缘对缘修复术（M-TEER）先后获FDA批准，用于原发性MR和FMR临床治疗后，FMR成为经导管二尖瓣介入治疗的焦点。Cardiac Dimensions（以下简称Cardiac）就是这样一家公司，致力于开发用于治疗HF和FMR的新型介入工具。其主导产品Carillon二尖瓣轮廓系统（Carillon Mitral Contour System®）是开创性的非手术设备，可以重塑二尖瓣并改善FMR症状。动脉网获悉，2023年4月26日，Cardiac的Carillon系统获得欧盟MDR认证。此前，Carillon系统已先后在2011年获得CE标志，2020年获得澳大利亚治疗用品批准（TGA）。给二尖瓣“搭桥”，超1500名患者接受Carillon系统治疗为了保证身体中的血液按照固定的方向循环流动，心脏中有四个单向开合的瓣膜，分别是主动脉瓣、二尖瓣、三尖瓣和肺动脉瓣。随着心脏有规律地收缩和舒张，各个瓣膜会相应的张开或闭合，从而保证血液的正向通过和防止反流。二尖瓣即心脏的左房室瓣，在左心室舒张时，瓣膜打开，血液从左心房顺利流入左心室；在左心室收缩时，瓣膜关闭，血液由左心室流向主动脉。二尖瓣是四个瓣膜中发病率最高的瓣膜，而二尖瓣反流（MR）是瓣膜病中最常见的疾病。Carillon二尖瓣轮廓系统是一种微创治疗系统，专为治疗FMR设计。Carillon系统可以固定二尖瓣，使其恢复正常形状，从而能够正常闭合，减少二尖瓣反流，能治疗二尖瓣反流等级为2+、3+和4+的患者。Carillon系统植入前后对比 图源：Cardiac官网Carillon系统可以在不损害二尖瓣瓣叶的情况下恢复二尖瓣的自然功能，由植入物和输送系统组成。植入物是一个类“桥状”器械，采用类似冠状窦形状，通过一个带状物将近端锚和远端锚连接在一起，该成形带利用心脏的静脉解剖结构来固定二尖瓣装置，通过输送系统可经右心入路将植入物输送到固定位置。Carillon 二尖瓣轮廓系统 图源：Cardiac官网Carillon系统可以通过经皮导管手术植入，并且不需要全身麻醉。首先在患者颈部划一个小切口，将导管插入术工具置入颈静脉，进入Carillon装置的放置位置，然后将部署Carillon装置的特殊导管引导至冠状窦（二尖瓣附近的静脉），最后植入Carillon装置，将其固定在冠状窦的最佳位置。Carillon系统植入过程 图源：Cardiac官网相较于缘对缘和其他动脉植入的直接瓣环成形术，Carillon装置具有几种优势。一、Carillon装置从颈静脉经右心系统入路，路径更短，植入时间大概需要一个小时；二、对于医生来说，经皮导管手术植入技术难度得以降低，易于操作，学习周期更短；三、由于Carillon是间接的、非接触式二尖瓣修复装置，它的置入不影响后续其他心衰手术的操作，可配合其它心衰治疗方案一起使用，也可在必要时将其取出。目前Carillon系统的市场业务已经发展到澳大利亚和欧洲，包括华盛顿州柯克兰、澳大利亚悉尼、德国法兰克福等，其中欧洲已有几个国家对Carillon系统提供医保报销，而在美国还处于研究阶段。迄今为止全球已有超过1500名患者使用Carillon系统进行治疗。融资总金额超2亿美元，打造超100年综合经验的管理团队Cardiac成立于2001年，总部位于美国华盛顿州柯克兰。Cardiac共进行过10轮融资，融资总资金超2亿美元，在资金驱动下，公司已开展过4轮独立试验，分别是AMADEUS、TITAN、TITAN II和REDUCE FMR。结果显示，接受Carillon治疗的FMR患者平均急性反流量减少8ml，并具有良好的长期（3年）生存率，大多数患者在12个月的临床治疗下，心衰症状明显减轻。但这四轮研究都是验证Carillon治疗FMR的安全性和性能，对于Carillon能治疗FMR并心衰患者的有效性还缺乏系统性研究。因此2021年，Cardiac宣布在美国启动EMPOWER临床试验，以评估Carillon治疗心衰的效果。Cardiac今年年初完成了D轮融资，获得的3500万美元将用于推动EMPOWER临床试验。Cardiac融资历史 数据来源：crunchbase成立二十多年，Cardiac在投资者的支持下打造完善技术的同时，也建立了专业的管理人才矩阵。公司的CEO兼首席执行官是Rick Wypych，Rick在金融、制造和生命科学行业拥有近30年的运营、财务和战略管理经验。Rick于2003年加入公司，担任过首席运营官和首席财务官，自2020年开始，他担任Cardiac的CEO兼首席执行官。Bob Calcote于2014年3月加入Cardiac，担任运营副总裁，曾担任RS Medical运营副总裁、ConforMIS运营高级副总裁、Archus运营副总裁和Spinal Dynamics运营副总裁，拥有30多年医疗器械运营、产品开发、监管和质量体系管理方面的经验，积累了40年的制造和工程经验。Angie Swenson于2023年加入Cardiac，被任命为临床副总裁，在过去20多年里，她一直在领导美国、欧洲、日本和加拿大的全球临床试验，管理人工心脏瓣膜、用于外周血管疾病的药物涂层球囊、去肾神经、急性心肌梗死的低温治疗的全球研究。她在医疗器械和心血管疾病的医疗技术上拥有超过15年的经验。公司的销售副总裁Carmelo Mastrandrea、治疗开发副总裁Guenter Haines、首席医疗官Steven Goldberg等，在销售、医疗器械研发等众多领域都积累了超10年的行业经验。在这样一个综合经验远超100年的管理团队领导下，Cardiac或将加速走上业务扩张之路。国内企业纷纷押注二尖瓣赛道，第一款国产TMV即将获批上市据蛋壳研究院报告显示，目前，外科手术是治疗二尖瓣反流的金标准，但有超过50%的中度二尖瓣反流患者因年龄和合并症的原因无法接受手术治疗，未进行治疗的手术患者的1年和5年的总死亡率分别为20%和50%。随着微创技术的不断发展，经导管二尖瓣（TMV）的介入治疗已经成为可能替代外科手术的一大研究热点。TMV各类术式都来源于外科手术，依照技术特点，其介入治疗可以分为两类：经导管二尖瓣置换（TMVR）和经导管二尖瓣修复（TMVr）。TMVR是将整个人工瓣膜植入原有二尖瓣，从而替代原有二尖瓣的生理功能。而TMVr则是针对原有二尖瓣具体解剖结构问题进行局部修复，仍然保留原有二尖瓣功能。经导管二尖瓣修复分类虽然TMVR置换操作相对容易，但面临安全、锚定、密封、输送、耐久等问题的考验。而TMVr在全球范围内，瓣环修复、腱索修复以及缘对缘瓣叶修复（TEER）都有通过CE认证的商业化产品。中国的TMV市场也十分火热，经蛋壳研究院统计，国内合计21家企业（其中2家外企：雅培，爱德华）布局此领域，TMV产品合计45个，其中TMVR有15个，TMVr有30个。而TMVr中的TEER是目前发展最为快速的一个赛道，国内TEER路径上布局的产品多达 20个（国产18个）。国内获批上市的经导管二尖瓣产品仅雅培的TEER产品MitraClip。有了雅培的先例，国内越来越多企业布局TMV赛道，如开发ValveClamp的捍宇医疗、开发DargonFly和MitralStich的德晋医疗、开发Valveclip-M的纽脉医疗等，都在此领域进行了积极探索。目前，进度最快即将商业化的产品是德晋医疗的DragonFly，以及捍宇医疗的ValveClamp。ValveClamp已于2022年7月递交国家药监局注册申请，有望成为中国首款商业化的国产二尖瓣反流介入治疗器械。近期推荐声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。动脉网，未来医疗服务平台